Basilea receives an additional USD 5.4 million from BARDA to continue development of its novel antibiotic Ceftibuten‑Ledaborbactam
Executive summary: Basilea announced an additional USD 5.4 million funding from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to continue development of its novel antibiotic Ceftibuten‑Ledaborbactam. The financing reinforces Basilea’s antibiotic R&D efforts and reflects ongoing BARDA investment in novel antimicrobials amid rising antibiotic resistance.
Who is involved: Basilea (Swiss pharmaceutical company), BARDA (U.S. HHS agency), and the Ceftibuten‑Ledaborbactam development program.
Likely next: Basilea will apply the funds toward further preclinical studies and clinical trial preparations for Ceftibuten‑Ledaborbactam.
The award adds to Basel‑based Basilea’s existing BARDA agreements, underscoring continued U.S. government support for its antibiotic pipeline. The funds are earmarked for further preclinical and clinical work on Ceftibuten‑Ledaborbactam, a molecule targeting drug‑resistant infections. While the amount is modest compared with earlier BARDA tranches, it signals sustained confidence in the project’s potential to address unmet medical needs.
Timeline
- — Basilea erhält zusätzliche USD 5.4 Mio. von BARDA zur Entwicklung des neuartigen Antibiotikums Ceftibuten-Ledaborbactam (GlobeNewswire)
- — Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix (GlobeNewswire)
- — Sapphiros Secures $12.4 Million BARDA Award to Advance Rapid Molecular Diagnostics for Biothreat Detection (PR Newswire)
Analysis — what this means
Sectors affected
- antibiotics R&D
- pharmaceuticals
Regulatory implications
- BARDA awards require compliance with U.S. Federal Acquisition Regulations (FAR) and milestone‑based reporting to the Department of Health and Human Services.
Historical parallels
- Basilea received USD 30 million from BARDA in July 2026 for phase‑3 development of the antifungal fosmanogepix
- Sapphiros secured a USD 12.4 million BARDA award in July 2026 for rapid molecular diagnostics
Key entities
Sources
- Basilea erhält zusätzliche USD 5.4 Mio. von BARDA zur Entwicklung des neuartigen Antibiotikums Ceftibuten-Ledaborbactam — GlobeNewswire
- Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix — GlobeNewswire
- Sapphiros Secures $12.4 Million BARDA Award to Advance Rapid Molecular Diagnostics for Biothreat Detection — PR Newswire